Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

L.A. McKeown

November 01, 2024

News Conference News TCT 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

Todd Neale

October 30, 2024

News Conference News TCT 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

Michael O'Riordan

October 27, 2024

News Conference News TCT 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Michael O'Riordan

November 01, 2023

News Conference News TCT 2023

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

L.A. McKeown

October 27, 2023

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

Presentation TCT 2023

Four-Year Outcomes From the EVOLUT Low Risk Trial

Presenter: Michael Reardon

October 24, 2023

News Conference News TCT 2022

Sizing Mismatch a Problem for Balloon-Expandable Valves in Small Annuli TAVI

Yael L. Maxwell

September 18, 2022

News Conference News TCT 2022

FLASH: More Data to Support Mechanical Thrombectomy in PE

L.A. McKeown

September 18, 2022

News Conference News TCT 2021

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

Michael O'Riordan

November 05, 2021

News Conference News TCT 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

Todd Neale

November 05, 2021

News Conference News TCT 2020

Acurate Neo Still Falls Short of Sapien 3 in SCOPE 1-Year Follow-up

Michael O'Riordan

October 23, 2020

News Conference News TCT 2020

Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results

Michael O'Riordan

October 16, 2020

News Conference News TCT 2020

Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2

Michael O'Riordan

October 15, 2020

News Conference News TCT 2019

Predicting Final Valve Position After TAVR: Different Devices, Different Success

Michael O'Riordan

October 07, 2019

News Conference News TCT 2019

TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3

Yael L. Maxwell

September 29, 2019

Presentation TCT 2019

Deep-Dive: NEW Insights From the Evolut Low-Risk Trial

Presenter: Michael Reardon

September 26, 2019

News Conference News TCT 2019

Personalized CT-Derived Modeling Guides Choices in Bicuspid Aortic Valve Disease

Michael O'Riordan

September 25, 2019

Presentation TCT 2019

COAPT, Partner 2, and Evolut Low-Risk Trial Synopsis and What They Mean Moving Forward

Presenter: Elizabeth Perpetua

September 25, 2019

News Conference News TCT 2018

PORTICO I: Low 1-Year Mortality With Repositionable TAVR Valve in OUS Experience

L.A. McKeown

September 27, 2018

Advertisement

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Four-Year Outcomes From the EVOLUT Low Risk Trial

Sizing Mismatch a Problem for Balloon-Expandable Valves in Small Annuli TAVI

FLASH: More Data to Support Mechanical Thrombectomy in PE

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

Acurate Neo Still Falls Short of Sapien 3 in SCOPE 1-Year Follow-up

Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results

Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2

Predicting Final Valve Position After TAVR: Different Devices, Different Success

TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3

Deep-Dive: NEW Insights From the Evolut Low-Risk Trial

Personalized CT-Derived Modeling Guides Choices in Bicuspid Aortic Valve Disease

COAPT, Partner 2, and Evolut Low-Risk Trial Synopsis and What They Mean Moving Forward

PORTICO I: Low 1-Year Mortality With Repositionable TAVR Valve in OUS Experience

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content